Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133022 | 1.00 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2BNT5E | |
| SCHEMBL7214818 | 0.90 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7214813 | 0.90 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7068573 | 0.90 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BNT5E | |
| SCHEMBL7068581 | 0.90 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BNT5E | |
| SCHEMBL6917844 | 0.86 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL724654 | 0.86 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6917842 | 0.86 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL724653 | 0.86 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7214807 | 0.86 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | claimed |
| EP-1317465-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| WO-2002022630-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-03-21 | — | — | WO | claimed |
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | disclosed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072597-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.